Triveni Bio
Triveni Bio is seeking an experienced Assistant Controller to lead and manage the accounting function during a period of growth and clinical progress. The role will oversee month‑end close, financial reporting, payroll, accounts payable, and ERP system optimization while ensuring compliance with U.S. GAAP and internal controls. It involves collaboration with cross‑functional teams and support for external audits, board materials, and ad‑hoc financial projects.
Triveni Bio is a clinical-stage biotechnology company taking a genetics-informed approach and leveraging advanced antibody engineering to develop first-in-class therapeutics for immune and inflammatory (I&I) diseases. The company's pipeline includes bispecific antibodies such as TRIV-573 and TRIV-509, targeting conditions like atopic dermatitis. Triveni's approach is rooted in human genetics and novel biology, aiming to redefine treatment paradigms for patients with uncontrolled inflammatory disease.
Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
Sep 23, 2025
Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis
May 21, 2025
Wilson Sonsini Advises Goldman Sachs Alternatives on Patent Matters Related to Series B Investment in Triveni Bio
Oct 18, 2024
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Triveni Bio.
54% above the average for this role